Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29884989 | 1.00 | CYP11B2 (0.73) | CYP11B2CYP19A1USP2TSHRCYP2C9 | |
| SCHEMBL1040095 | 0.91 | CYP11B2 (0.87) | CYP11B2CYP19A1USP2TSHRCYP2C9 | |
| SCHEMBL1076732 | 0.90 | CYP11B2 (0.80) | CYP11B2CYP19A1CYP11B1TACR3 | |
| SCHEMBL1040118 | 0.85 | CYP11B2 (0.70) | CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL13563947 | 0.85 | CYP11B2 (0.87) | CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL1040020 | 0.84 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1TACR3 | |
| SCHEMBL1036330 | 0.84 | CYP11B2 (0.75) | CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL1040314 | 0.83 | CYP11B2 (0.67) | CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL1036640 | 0.83 | CYP11B2 (0.78) | CYP11B2CYP19A1USP2MEN1KMT2A | |
| SCHEMBL1041248 | 0.82 | CYP11B2 (0.63) | CYP11B2CYP19A1ALDH1A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3527208-A1 | USE OF AN ADRENAL HORMONE-MODIFYING AGENT | Novartis AG (CH) | 2019-08-21 | — | — | EP | disclosed |
| EP-2523731-B1 | USE OF AN ADRENAL HORMONE-MODIFYING AGENT | NOVARTIS AG (CH) | 2018-10-24 | — | — | EP | disclosed |
| US-9434754-B2 | Use of an adrenal hormone-modifying agent | NOVARTIS AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2256118-B1 | Condensed imidazolo derivatives for the inhibition of aromatase and the treatment of aldosterone related diseases | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8835646-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| US-8835646-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| US-20120277215-A1 | Organic Compounds | RECORDATI AG (CH) | 2012-11-01 | — | — | US | disclosed |
| CN-102711916-A | Use of adrenal hormone modulators | NOVARTIS AG | 2012-10-03 | — | — | CN | disclosed |
| WO-2011088188-A1 | USE OF AN ADRENAL HORMONE-MODIFYING AGENT | NOVARTIS AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| WO-2011061271-A1 | SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| EP-2270011-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270011-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2256118-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049616-A1 | Organic compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B2 14/4885CYP19A1 1/4885USP2 3271/4885 |
| US-20120277215-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B2 14/4885CYP19A1 1/4885USP2 3271/4885 |
| US-20140357621-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B2 14/4885CYP19A1 1/4885USP2 3271/4885 |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | MME, REN, AGTR1 | CYP11B2 2293/4885CYP19A1 1650/4885USP2 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.